
New medication to keep an eye on for EMA approval
Hi all. Just wanted to share that this new medication has been approved by the FDA and worth keeping an eye on for when it's approved in Europe.
In a nutshell: "Simtriyo (centanafadine) stands out from existing ADHD treatments because it is a first-in-class triple reuptake inhibitor that simultaneously boosts three key brain chemicals—norepinephrine, dopamine, and serotonin—whereas traditional medications only target one or two. This unique mechanism allows it to offer the clinical benefits of a non-stimulant, such as a lower risk of abuse and fewer sleep disruptions, while working much faster than older non-stimulants that typically take weeks to become effective. By balancing all three neurotransmitters at once, it aims to provide rapid symptom relief with a lower risk of the cardiovascular or emotional side effects frequently caused by standard stimulants."